TY - JOUR T1 - Plant Formulation ATRICOV 452 in Improving the Level of COVID-19 Specific Inflammatory Markers in Patients JF - medRxiv DO - 10.1101/2021.10.07.21264491 SP - 2021.10.07.21264491 AU - Latha Damle AU - Hrishikesh Damle AU - BR Bharath Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/09/2021.10.07.21264491.abstract N2 - Due to the huge demand for health care facilities, there is a need for safe therapeutic intervention which can reduce the need for extensive health care support. In that regard, the current study was aimed at performing Phase 1 clinical trial to determine the safety of plant formulation in 24 healthy volunteers and Phase 2 trials in 100 COVID-19 patients to determine the tolerability and impact on the level of COVID 19 specific inflammatory markers. The outcomes of the Phase 1study have suggested the safe usage of plant formulation in humans and encouraged to conduct Phase 2 clinical trial. In the Phase 2 trial, the plant formulation was evaluated in 100 COVID-19 patients along with the standard of care. In Phase 1 single dose of 500 mg plant formulation capsule was used as an intervention, while 1gm thrice a day of plant formulation for 14 days was the testing dose for Phase 2. During the Phase 1 trial, no adverse event was observed and all organ systems were normal in function. During the Phase 2 trial, 100 patients underwent randomization, 50 were assigned to receive plant formulation, and 50 to receive placebo. Three patients in the placebo and two patients in the plant formulation group had dropped out from the study. Hence, the primary analysis population included 95 patients (48 allocated to plant formulation and 47 to placebo). The COVID 19 specific inflammatory markers improved faster and became normal in the plant formulation treatment group. In conclusion, the plant formulation (ATRICOV 452) has been found to be safe in phases 1 and 2.Trial Registration Phase 1: CTRI Registration number: CTRI/2020/09/027660Phase 2: CTRI Registration number: CTRI/2021/01/030795Competing Interest StatementLatha Damle is the founder of Atrimed Biotech LLP and holds equity in Atrimed Pharmaceuticals. Hrishikesh Damle holds equity shares in Atrimed Pharmaceuticals.Clinical TrialPhase 1: CTRI Registration number: CTRI/2020/09/027660 Phase 2: CTRI Registration number: CTRI/2021/01/030795Clinical Protocols http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=47086&EncHid=&userName=CTRI/2020/09/027660 http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=51391&EncHid=&userName=CTRI/2021/01/030795 Funding StatementThe study was sponsored by Atrimed Pharmaceuticals Pvt. Ltd and no external funding was received for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Vedant Hospital Institutional Ethics Committee (VHIEC) and Lifepoint Research Ethics committee on January 13, 2021 and March 13, 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is archived, available at trial site and with the sponsor. ER -